Shopping Cart
- Remove All
Your shopping cart is currently empty
GSK2239633A
🥰Excellent
Catalog No. T11481Cas No. 1240516-71-5
GSK2239633A is an allosteric antagonist of CC-chemokine receptor 4 (CCR4) with a pIC50 of 7.96 for the binding of [125I]-TARC to human CCR4.
GSK2239633A
🥰Excellent
Purity: 99.78%
Catalog No. T11481Cas No. 1240516-71-5
GSK2239633A is an allosteric antagonist of CC-chemokine receptor 4 (CCR4) with a pIC50 of 7.96 for the binding of [125I]-TARC to human CCR4.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $32 | In Stock | |
| 5 mg | $76 | In Stock | |
| 10 mg | $127 | In Stock | |
| 25 mg | $273 | In Stock | |
| 50 mg | $395 | In Stock | |
| 100 mg | $573 | In Stock | |
| 500 mg | Inquiry | In Stock | |
| 1 mL x 10 mM (in DMSO) | $94 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "GSK2239633A"
Pirfenidone
Cited
S-7701,AMR-69, S-7701, AMR69
T238653179-13-8
Pirfenidone (AMR69) inhibits the production of CCL2 and CCL12 in fibroblasts and also decreases TGF-β2 protein levels. Pirfenidone is an antifibrotic agent that is commonly used in studies related to pulmonary fibrosis and also has anti-inflammatory activity.
- $30
Size
QTY
CitedVercirnon
Traficet-EN, GSK-1605786, CCX282-B
T17225698394-73-9
Vercirnon (Traficet-EN) is a selective and potent antagonist of CCR9 (IC50: 10 nM). It is also used in the research of inflammatory bowel diseases.
- $107
Size
QTY
AZD2098
T4300566203-88-1
AZD2098 is a potent CC-chemokine receptor 4 (CCR4) inhibitor used for asthma research.
- $30
Size
QTY
BMS-817399
BMS817399
T268611202400-18-7In house
BMS-817399 is an orally active antagonist of CCR1 with IC50s of binding affinity and chemotaxis inhibition potencies and can be used in studies about rheumatoid arthritis.
- $163
Size
QTY
PF-4136309
PF 4136309, INCB8761
T34301341224-83-6
PF-4136309 (INCB8761) is a specific, effective, and orally bioavailable CCR2 antagonist.
- $30
Size
QTY
CCR6 antagonist 1
T60145588674-64-0
CCR6 antagonist 1, a chemical compound acting as a CCR6 antagonist, effectively inhibits the CCL20/CCR6 axis. Its utility lies in research focused on autoimmune-mediated inflammatory diseases, including inflammatory bowel diseases (IBDs).
- $31
Size
QTY
CCR2 antagonist 5
JNJ-41443532 Free Base, JNJ-41443532, JNJ41443532, JNJ 41443532
T276821228650-83-6In house
CCR2 antagonist 5 (JNJ-41443532) is a selective and orally active hCCR2 inhibitor with good binding affinity (IC50=37 nM) and potent functional antagonism (chemotaxis IC50=30 nM).JNJ-41443532 binds mCCR2 with a Ki of 9.6 µM, which can be used to study inflammatory diseases and diabetes. diseases and diabetes.
- $100
Size
QTY
INCB-9471
T71665869769-98-2In house
INCB-9471 is a CCR5 antagonist with anti-HIV activity and inhibits the interaction between HIV-1 gp120.
- $628
Size
QTY
MLN-3897 TFA
MLN-3897 TFA(1010731-97-1 Free base)
T28072L
MLN-3897 TFA is a potent CCR1 antagonist that inhibits the binding of 125I-MIP-1α to THP-1 cell membranes.
- $117
Size
QTY
CCR3 antagonist 1
T10156879399-82-3In house
CCR3 antagonist 1 is a potent CCR3 antagonist used in researching inflammatory and immunologic diseases.
- $93
Size
QTY
Aplaviroc
ONO-4128, GW 873140, GSK 873140, AK 602
T14307461443-59-4In house
Aplaviroc (AK 602), an SDP derivative, is a CCR5 antagonist with IC50 values of 0.1-0.4 nM for HIV-1Ba-L, HIV-1JRFL, and HIV-1MOKW.
- $545
Size
QTY
C-021
4-​Quinazolinamine, 2-​[1,​4'-​bipiperidin]​-​1'-​yl-​N-​cycloheptyl-​6,​7-​dimethoxy-
T21870864289-85-0In house
C 021 dihydrochloride is a potent CCR4 antagonist. C-021 (4-Quinazolinamine, 2-[1,4'-bipiperidin]-1'-yl-N-cycloheptyl-6,7-dimethoxy-) dihydrochloride potently inhibits functional chemotaxis in humans and mice with IC50s of 140 nM and 39 nM, respectively. It effectively prevents human CCL22-derived [35S]GTPγS from binding to the receptor (IC50: 18 nM).
- $47
Size
QTY
Select Batch
Purity:99.78%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | GSK2239633A is an allosteric antagonist of CC-chemokine receptor 4 (CCR4) with a pIC50 of 7.96 for the binding of [125I]-TARC to human CCR4. |
| Targets&IC50 | [125I]-TARC-CCR4:7.96(pIC50) |
| In vitro | GSK2239633A increases the CCL17-induced F-actin content of human CD4+ CCR4+ T cells with a pEC50 value of 8.79±0.22[1]. GSK2239633A inhibits thymus- and activation-regulated chemokine-induced (TARC)-induced increases in the F-actin content of isolated human CD4+ CCR4+ T-cells with a pA2 of 7.11±0.29[3]. |
| In vivo | GSK2239633A demonstrates good pharmacokinetic data in preclinical animal studies with bioavailability in rats and beagle dogs of 85% and 97% respectively[2]. Plasma GSK2239633A (i.v.) displays rapid, bi-phasic distribution and slow terminal elimination (13.5 h), suggesting that GSK2239633A is a low to moderate clearance drug. Blood levels of GSK2239633A(oral) reach Cmax rapidly (median tmax: 1.0-1.5 hours)[3]. |
| Molecular Weight | 549.06 |
| Formula | C24H25ClN4O5S2 |
| Cas No. | 1240516-71-5 |
| Smiles | COc1cccc2n(Cc3cccc(CNC(=O)C(C)(C)O)c3)nc(NS(=O)(=O)c3ccc(Cl)s3)c12 |
| Relative Density. | 1.45 g/cm3 (Predicted) |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 250 mg/mL (455.32 mM) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy GSK2239633A | purchase GSK2239633A | GSK2239633A cost | order GSK2239633A | GSK2239633A chemical structure | GSK2239633A in vivo | GSK2239633A in vitro | GSK2239633A formula | GSK2239633A molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.